Differential modification of genetic susceptibility to childhood eczema by two probiotics

Morgan, Angharad R.; Han, Dug Yeo; Wickens, Kristin; Barthow, Christine; Mitchell, Edwin A.; Stanley, Thorsten; Dekker, James; Crane, Julian; Ferguson, Lynnette R.

doi:10.1111/cea.12394

Cited by 23 publications

(21 citation statements)

References 53 publications

(80 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…in the HN019 group had significantly reduced risks of eczema compared with infants who received placebo. 18 Several of these eczema gene variants occur in genes encoding proteins involved in the immune system, suggesting that HN001 supplementation particularly benefits those with a genetic predisposition towards a less balanced Th1/Th2 response. Other eczema gene variants which interacted with probiotic supplementation occurred in genes encoding proteins involved in skin barrier function such as DEFB1 and SPINK5, indicating a particular benefit of HN001 for those with a genetic predisposition towards poorer skin (and intestinal epithelial) barrier function.…”

Section: Discussionmentioning

confidence: 99%

Effects of Lactobacillus rhamnosus HN001 in early life on the cumulative prevalence of allergic disease to 11 years

Wickens

Barthow

Mitchell

et al. 2018

Pediatric Allergy Immunology

View full text Add to dashboard Cite

Background:In a two-centre randomized placebo-controlled trial of Lactobacillus rhamnosus HN001 (HN001) (6 × 10 9 colony-forming units [cfu]) or Bifidobacterium lactis HN019 (HN019) (9 × 10 9 cfu) taken daily from 35-week gestation to 6 months' post-partum in mothers while breastfeeding and from birth to age 2 years in infants, we showed that HN001 significantly protected against eczema development at 2, 4 and 6 years and atopic sensitization at 6 years. There was no effect of HN019. We report here the findings for 11 year outcomes. Methods:At age 11 years, eczema was defined as previously using the UK Working Party's Diagnostic Criteria. Asthma, wheeze, hay fever and rhinitis were defined based on the International Study of Asthma and Allergies in Childhood (ISAAC) questions. Atopic sensitization was defined as one or more positive responses (mean wheal diameter ≥3 mm) to a panel of food and aeroallergens. Analysis was intentionto-treat using hazard ratios to assess probiotic effects on the 11-year lifetime prevalence and relative risks for point or 12-month prevalence at 11 years.Results: Early childhood HN001 supplementation was associated with significant reductions in the 12-month prevalence of eczema at age 11 years (relative risk[RR] = 0.46, 95% CI 0.25-0.86, P = 0.015) and hay fever (RR = 0.73, 95% CI 0.53-1.00, P = 0.047). For the lifetime prevalence, HN001 was associated with a significant reduction in atopic sensitization (hazard ratio [HR] = 0.71, 95% CI 0.51-1.00, P = 0.048), eczema (HR = 0.58, 95% CI 0.41-0.82, P = 0.002) and wheeze (HR = 0.76, 95% CI 0.57-0.99, P = 0.046). HN019 had no significant effect on these outcomes.Conclusion: This is the first early probiotic intervention to show positive outcomes for at least the first decade of life across the spectrum of allergic disease. K E Y W O R D Sasthma, Bifidobacterium lactis HN019, eczema, hay fever, Lactobacillus rhamnosus HN001, probiotics, randomized controlled trial, rhinitis, wheeze

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Lactobacillus rhamnosus HN001 in early life on the cumulative prevalence of allergic disease to 11 years

Wickens

Barthow

Mitchell

et al. 2018

Pediatric Allergy Immunology

View full text Add to dashboard Cite

show abstract

“…Because they are more resistant to harsh environmental conditions, strains of B. animalis subsp. lactis have been studied more than those of other members of the genus Bifidobacterium, and clinical studies demonstrated their healthpromoting attributes in some gastrointestinal disorders and allergic processes (4)(5)(6).…”

mentioning

confidence: 99%

A Single Mutation in the Gene Responsible for the Mucoid Phenotype of Bifidobacterium animalis subsp. lactis Confers Surface and Functional Characteristics

Hidalgo-Cantabrana

Sánchez

Álvarez‐Martín

et al. 2015

Appl Environ Microbiol

View full text Add to dashboard Cite

Exopolysaccharides (EPS) are extracellular carbohydrate polymers synthesized by a large variety of bacteria. Their physiological functions have been extensively studied, but many of their roles have not yet been elucidated. We have sequenced the genomes of two isogenic strains of Bifidobacterium animalis subsp. lactis that differ in their EPS-producing phenotype. The original strain displays a nonmucoid appearance, and the mutant derived thereof has acquired a mucoid phenotype. The sequence analysis of their genomes revealed a nonsynonymous mutation in the gene Balat_1410, putatively involved in the elongation of the EPS chain. By comparing a strain from which this gene had been deleted with strains containing the wild-type and mutated genes, we were able to show that each strain displays different cell surface characteristics. The mucoid EPS synthesized by the strain harboring the mutation in Balat_1410 provided higher resistance to gastrointestinal conditions and increased the capability for adhesion to human enterocytes. In addition, the cytokine profiles of human peripheral blood mononuclear cells and ex vivo colon tissues suggest that the mucoid strain could have higher anti-inflammatory activity. Our findings provide relevant data on the function of Balat_1410 and reveal that the mucoid phenotype is able to alter some of the most relevant functional properties of the cells.T he genus Bifidobacterium includes commensal microorganisms commonly found in the human gut. Some strains, belonging mainly to the species Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium bifidum, and Bifidobacterium animalis, have been used as probiotics, since there is scientific evidence that links the administration of these bacteria with specific health benefits (1, 2). In particular, B. animalis subsp. lactis has a robust phenotype that allows growth at high numbers in commercial applications under nonanaerobic conditions. Furthermore, strains of this subspecies survive the gastric passage and reach the intestinal tract in a metabolically active state, being also the most common representatives of bifidobacteria in functional food products (3). Because they are more resistant to harsh environmental conditions, strains of B. animalis subsp. lactis have been studied more than those of other members of the genus Bifidobacterium, and clinical studies demonstrated their healthpromoting attributes in some gastrointestinal disorders and allergic processes (4-6).Exopolysaccharides (EPS) are extracellular layers of carbohydrates typically found in microorganisms (7). EPS production has been involved in a variety of physiological processes that have implications for the producer microorganism and the host (8, 9). Specifically, in intestinal bacteria some of the most relevant roles attributed to EPS are the favoring of intestinal colonization and survival (10-12) and immunomodulation (11,13,14).A common set of functional modules, including the synthesis of activated sugar precursors, cytoplasmic assembly of the EPS unit, export...

show abstract

“…The hypothesis that probiotics may be used in the management of allergic disease and eczema was supported by evidence that the composition of intestinal microbiota in children affected by allergic disease and/or eczema was different than the gut microbiota of healthy subjects, and often these differences have been observed to precede the development of the aforementioned diseases (Watanabe et al, 2003). Morgan et al (2014) investigated whether the probiotic microorganisms Lactobacillus rhamnosus and Bifidobacterium animalis subsp, lactis were able to modify the genetic predisposition to eczema conferred by genetic variation in susceptibility genes in children. Morgan et al (2014) investigated whether the probiotic microorganisms Lactobacillus rhamnosus and Bifidobacterium animalis subsp, lactis were able to modify the genetic predisposition to eczema conferred by genetic variation in susceptibility genes in children.…”

Section: Probiotics: An Innovative Therapeutic Strategymentioning

confidence: 99%

“…As a consequence, the intestinal dysbiosis may cause or worsen allergic diseases, reinforcing the hypothesis that probiotic bacteria may be used for the prevention and treatment of allergies and eczema. It is possible that some probiotics microorganisms are able to readjust the immune system away from a proallergic response, while others may exert their action in overcoming the defects in skin barrier as a result of genetic variation in genes, such as DEFB1 and SPINK5, which encode epidermal and epithelial structural proteins, respectively (Morgan et al, 2014). The authors observed that children who carried a genetic variant that put them at a higher risk of developing eczema were significantly less susceptible to develop eczema if they took the L. rhamnosus strain, compared to those who took the B. lactis strain or children in the placebo group.…”

Section: Probiotics: An Innovative Therapeutic Strategymentioning

confidence: 99%

“…Morgan et al (2014) investigated whether the probiotic microorganisms Lactobacillus rhamnosus and Bifidobacterium animalis subsp, lactis were able to modify the genetic predisposition to eczema conferred by genetic variation in susceptibility genes in children. This protein has antimicrobial and immune-regulatory properties and evidence suggests that a low concentration of hBD-1 may lead to an increased risk of infections and allergic disease development (Morgan et al, 2014). The specific role of probiotic on eczema is still unclear, as are the reasons why different bacterial strains seem to have different actions on the human organism.…”

Section: Probiotics: An Innovative Therapeutic Strategymentioning

confidence: 99%

See 1 more Smart Citation

Probiotics

Drago

Toscano

2016

Probiotics, Prebiotics, and Synbiotics

View full text Add to dashboard Cite

Differential modification of genetic susceptibility to childhood eczema by two probiotics

Cited by 23 publications

References 53 publications

Effects of Lactobacillus rhamnosus HN001 in early life on the cumulative prevalence of allergic disease to 11 years

Effects of Lactobacillus rhamnosus HN001 in early life on the cumulative prevalence of allergic disease to 11 years

A Single Mutation in the Gene Responsible for the Mucoid Phenotype of Bifidobacterium animalis subsp. lactis Confers Surface and Functional Characteristics

Probiotics

Contact Info

Product

Resources

About